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Abstract
Oral Cancer is one of the most common malignancies of the head and neck 
region. Despite technological advancements and improvements in Oral cancer 
diagnosis and treatment modalities, the 5-year survival rate remains low and is 
associated with poor prognosis and high mortality rate especially when detected at a 
later stage. The empirical therapy followed for the treatment of oral cancer includes 
surgery, radiotherapy and chemotherapy. The treatments are not equally efficacious 
for all patients, are associated with side effects and poor prognosis. The need of 
the hour is early diagnosis and tailored treatment therapies for individual patients. 
With the advent of immunotherapy, the cancer treatment has moved toward 
personalised precision medicine which tailors’ treatments to each individual. 
Personalised precision medicine incorporates, molecular profiling of tumours with 
OMICS technology, biomarkers and companion diagnostics to build databases of 
patients and devise tailor made treatment approaches for individual patients. This 
article discusses the role of precision medicine in OSCC prevention, detection, and 
management by reviewing our understanding of OC from both genetic and OMICS 
perspectives.
Keywords: Personalised precision medicine, OMICS, Genomics, Transcriptomics, 
Proteomics, Metabolomics, Big data, Targetted therapy, Immunotherapy
1. Introduction
Oral cancer is a type of head and neck cancer (HNC), which encompasses a wide 
range of tumour types that arise from a variety of anatomic structures, including 
the oral cavity, oropharynx, larynx, hypopharynx, and nasopharynx. Squamous 
cell carcinomas (OSCCs) account for over 90% of these malignancies histopatho-
logically, with over 50% occurring in the oral cavity [1]. Tobacco usage (smoked 
or chewed), arecanut, excessive alcohol use, and/or human papillomavirus (HPV) 
infection are the most major and well-established risk factors associated with this 
neoplasm [2–4].
Cancer is a major public health concern around the world. According to the 
International Agency for Research on Cancer’s GLOBOCAN project, there were 
approximately 14.1 million newly diagnosed cancer cases and 8.2 million deaths 
worldwide in 2012.Oral cancer is one of the most common cancers worldwide, 
accounting for 2% of all cancer cases and having a nearly 50% mortality rate [5]. 
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Oral and pharyngeal tumours are the sixth most common cancer worldwide [6]. 
Internationally, South Asian countries such as Sri Lanka, India, and Taiwan have 
the highest rates of oral cancer, which can be attributed to high rates of cigarette 
smoking and areca nut use in these countries [7].
Despite technological advancements and improvements in OSCC diagnosis 
and treatment modalities, the 5-year survival rate remains low, hovering around 
50–60%, ranging from 80% for stage I cancers to 40% for stage IV cancers. This 
disparity can be explained by the delay in diagnosis as well as the relatively high 
tumour recurrence rates found in these patients. In general, only one-third of OSCC 
patients have the disease in its early stages at the time of diagnosis (I and II) [8].
Treatment strategies for OSCC differ depending on the stage of the disease 
at the time of diagnosis. Patients with localised disease are typically treated with 
surgery and/or radiotherapy, which results in a high chance of long-term survival 
but significant morbidity. Chemotherapy and radiotherapy and recently immuno-
therapy are the mainstays of treatment for metastatic OSCC [9]. Despite advances 
in understanding the pathobiological mechanisms of OSCC, the prognosis has not 
improved over the last few decades. This is largely due to the high morbidity and 
mortality rates associated with local and regional OSCC recurrences. The clinical 
challenge remains in detecting regional metastasis accurately and efficiently treat-
ing second primary OSCC and recurrent tumours [10].
The practise of medicine is still primarily empirical today, with doctors relying 
on pattern matching to make diagnoses based on a patient’s medical history, physi-
cal examination, and test data. As a result, a prescribed treatment is frequently 
dependent on a physician’s previous experience with patients with comparable 
symptoms. As a result, the best drug may be given for a “typical patient” with a 
certain condition. The treatment decisions are made through trial and error, and 
patients may experience unforeseen adverse effects or poor or no efficacy for a 
medicine that theoretically works in some people with that disease [11].
Traditional therapeutic procedures have a poor prognosis and are associated 
with negative side effects. Immunotherapy adoption has moved the field of cancer 
treatment toward the concept of precision and personalised medicine (PPM), 
which tailors’ treatments to each individual. For cancer treatment, there are two 
options: the traditional approach and the PPM model. The fundamental distinc-
tions between the classic cancer treatment approach and the developing precision 
and personalised medicine (PPM) concept are compared. Traditionally, cancer has 
been treated with “one-size-fits-all” treatments including chemotherapy, radiation, 
and surgical tumour removal. These treatments have a wide range of efficacy in 
different people, and they frequently destroy healthy, noncancerous organs and 
tissues. Individualised therapy customised to specific tissues, gene alterations, and 
personal characteristics relevant to each unique case of cancer characterise the PPM 
approach [12].
This article discusses the role of precision medicine in OC prevention, detection, 
and management by reviewing our understanding of OC from both genetic and 
OMICS perspectives.
2. Why personalised precision medicine (PPM)
Traditionally Surgery, Radiotherapy and chemotherapy have been used in the 
treatment of OC. Some people will only need one treatment, but most people will 
need a combination of medicines to combat cancer’s resistance. When there are 
solid tumours that have not metastasized and are in easily accessible places of the 
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body, surgery can be utilised; nevertheless, many cancers do metastasis, necessitat-
ing more harsh therapies such as radiotherapy and chemotherapy. High doses of 
radiation and medicines are used in these methods to kill cancer cells and shrink 
tumours, but they often inflict additional damage to healthy cells [13]. It is stated 
that the given class of cancer medications is projected to be useless in up to 75% 
of patients The success of these treatments is influenced by a variety of factors, 
including the type, stage, and location of the cancer, as well as the patient’s age 
and overall condition. This shows that before choosing a cancer treatment, vari-
ous personal aspects should be examined [14]. Over the last decade, it has been 
increasingly obvious that no two patients’ malignancies are exactly the same, and 
therefore generic treatments like chemotherapy and radiation may have varying 
outcomes. This standard cancer treatment strategy is extremely simple, resulting 
in ineffective, expensive treatments and unwanted side effects for patients [15]. 
It is well understood that a treatment’s response varies across the variability of a 
population, including good and poor responders. Variables such as genetic predis-
position, cohort heterogeneity, ethnicity, slow vs. quick metabolizers, epigenetic 
factors, and early vs. late stage of disease affect patient and therapy response. 
These variables influence whether or not a person will respond well to a certain 
treatment [11].
Immunotherapy, which uses a patient’s own immune system to combat cancer, 
is another type of cancer treatment that has cleared the way for more specific and 
successful treatments. Monoclonal antibodies (mAbs), checkpoint inhibitors, 
cytokines, vaccinations, and adoptive cell transfer, most notably in the form of 
haematopoietic stem cell transplants (HSCTs) and chimeric antigen receptor (CAR) 
T-cell therapies, are examples of immunotherapy treatments [16]. Targeted thera-
peutics, such as cetuximab (monoclonal epidermal growth factor receptor [EGFR] 
antibody), bevacizumab (monoclonal vascular endothelial growth factor [VEGF] 
antibody), and mechanistic target of rapamycin (mTOR) inhibitors, have recently 
been introduced into treatment regimens or ongoing clinical trials to improve sur-
vival rate and reduce toxicity. With the advancement of immunotherapy, the Food 
and Drug Administration (FDA) has approved monoclonal antibodies that target 
programmed cell death protein-1 (PD-1), a receptor of the immune escape pathway, 
such as nivolumab and pembrolizumab, for recurrent and/or metastatic head and 
neck SCC [9]. Immunotherapy adoption has moved the field of cancer treatment 
toward the concept of personalised precision medicine (PPM), which tailors’ treat-
ments to each individual.
The purpose of PPM is to allow doctors to forecast the best course of action for 
a patient promptly, effectively, and precisely. Clinicians will require tools that are 
both compatible with their clinical workflow and cost-effective in order to achieve 
this. These techniques can make managing the biological complexity that underpins 
human diseases a lot easier. A PPM ecosystem is under constant development to 
enable the creation and refining of such tools, and it is the solution to the problem. 
Precision medicine emphasises the need of combining established clinical indica-
tors with molecular profiling to provide diagnostic, prognostic, and therapeutic 
techniques tailored to the individual needs of each patient group. For the optimal 
utilisation of the PM ecosystem, accurate data interpretation is required. The PM 
ecosystem brings together omics and clinical data to solve problems [11].
A move from empirical treatment to PPM is now possible thanks to increased 
usage of Biomarkers and companion diagnostics (CDX) (the right medicine, for 
the right patient, at the right dose, at the right time) [17]. PPM is a more effective 
model that is ready to disrupt the “one size fits all” approach. Based on the measure-
ment and manipulation of essential patient genetic and omic data, this perspective 
Oral Cancer - Current Concepts and Future Perspectives
4
promotes the creation of customised treatments for each individual subtype of 
cancer (transcriptomics, metabolomics, proteomics, etc.) [12].
Based on the definition provided by the National Cancer Institute, Personalised 
Precision Medicine, (PPM) is “an approach to patient care that allows doctors to 
select treatments that are most likely to help patients based on a genetic under-
standing of their disease.”
2.1 The PPM method and its use to cancer therapy
Patients with a cancer are enrolled randomly to prevent bias in traditional drug 
development, employing a “all comers” method with the assumption that the 
enrolled patients are nearly homogeneous. The purpose of random enrollment is 
to guarantee that the general population is well represented. In practise, we never 
conduct clinical trials on patients who are randomly chosen; instead, we apply 
various forms of enrichments to patients’ enrolment by using particular inclu-
sion and exclusion criteria. Despite all of the efforts to enrich the community, the 
population that is ultimately chosen for the study can be quite diverse in terms 
of drug-metabolising capacity, environmental factors (e.g., nutrition, smoking 
habits, lifestyle, etc.), prior medication(s) exposure, and an individual’s genetic 
and epigenetic make-up are all factors to consider. BMs are being used to better 
define molecular, genetic, and environmental changes. Drug developers have been 
studying the epigenetic makeup of patients and attempting to take a more objec-
tive stance.
Patient stratification is used to distinguish between likely responders and 
non-responders. When compared to randomly selected individuals, prospective 
stratification can result in a smaller and shorter clinical study. At a bare mini-
mum, stratification can expedite approval for medication candidates targeted 
at a subset of patients while providing room for additional testing and market 
development in the more heterogeneous patient group. In the best-case scenario, 
it can reveal an effective therapeutic agent that would otherwise be lost in the 
noise generated by non-responders, as was the case with trastuzumab and 
gefitinib. This will not only decrease the duration of the clinical trial but will also 
be cost effective [18].
Scientists were able to read and understand an individual’s genetic code, as 
well as detect hereditary predispositions to particular diseases, when the Human 
Genome Project (HGP) was completed. This watershed moment shifted the focus 
of health care from reactive to proactive. Scientists are currently striving to gain 
a detailed understanding of the body’s function at numerous omics levels, as well 
as characterise how environmental exposures alter genetic predispositions. When 
all of this data is combined, scientists and doctors will be able to better anticipate 
how patients will respond to a particular treatment. CDx assays patients for genetic 
features that determine whether or not they will respond to a specific medication. 
This technique has the potential to have a significant impact on the patient’s care. 
The transformation from a clinician choosing a generic medicine that is more or less 
experimental for the patient to one that effectively addresses the disease with PPM 
is the revolution [12].
2.2 Steps in PPM
1. Acquiring PPM data
2. Developing a PPM therapy
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2.3 Acquiring PPM data
2.3.1 Tools for PPM
2.3.1.1 Biomarkers
Predictive BM for immunotherapy differs from typical BM used for targeted 
therapies in the case of cancer immunotherapy. Because of the complexity of the 
tumour microenvironment (TME), immune response, and molecular profiling, a 
more holistic approach is required than using a single analyte BM [3]. To address 
this issue, researchers have developed a multiplexing strategy, in which numerous 
BMs are used to provide more precise patient stratification. Histological analysis 
now includes concomitant analysis of immuno-oncology BMs, such as PD-L1 and 
immune cell infiltrates (Figure 1), as well as more comprehensive immune and 
tumour-related pathways (Figure 2) (the “Cancer Immunogram”). Multiplexed 
immunoprofiling, which generates a comprehensive biomarker collection that may 
be associated with clinical parameters, is critical for the effectiveness of PM in 
cancer immunotherapy [21, 22].
A specific gene or mutation must be linked to a clinical result before a PPM 
treatment can be created and utilised in patients. This is a significant endeavour; 
discovering a therapeutically relevant phenotype or polymorphism might take years 
of research involving many scientists. Furthermore, determining which polymor-
phisms cause patients to have a good or negative therapy response necessitates 
additional research. Sequencing DNA from a large number of people is the first step 
in deciphering the genetic code. This phase is becoming easier with the improve-
ment of sequencing technologies. The most difficult issues are in interpreting these 
massive data sets, which is where bioinformatics comes in.
Figure 1. 
Critical checkpoints for host and tumour profiling. A multiplexed biomarker approach is highly integrative and 
includes both tumour- and immune-related parameters assessed with both molecular and image-based methods 
for individualised prediction of immunotherapy response. Byassessing patient samples continuously one can 
collect a dynamic data on tissue-based parameters, such as immune cell infiltration and expressionof immune 
checkpoints, and pathology methods. These parameters are equally suited for data integration with molecular 
parameters. TILs: Tumour-infiltrating lymphocytes. PD-L1: Programmed cell death-ligand 1. Immunoscore: A 
prognostic tool for quantification of in situ immune cell infiltrates. Immunocompetence: body’s ability to produce 
a normal immune response following exposure to an antigen (tumour drawing has been adapted from [19].
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Without the enormous achievement of sequencing the human genome, the 
discipline of PPM would not exist. From 1990 until 2003, the HGP took 13 years to 
complete. The International Human Genome Sequencing Consortium (IHGSC), 
which includes over 200 collaborators from 19 nations, was tasked with discover-
ing new knowledge regarding the structure and organisation of the genome. The 
human genome has around 20,500 genes, and any two persons share 99.99 percent 
of their genome, implying that genetic individuality can be identified only in the 
remaining 0.01 percent. Long repeat sequences were also discovered in the genome, 
and single-base changes (single nucleotide polymorphisms [SNPs]) were found to 
have the potential to be distinct disease indicators. The use of bacterial artificial 
chromosomes (BAC) and Sanger sequencing aided in the early data collection. BAC 
vectors helped with the first stage of genome sequencing by determining the chro-
mosomal location of DNA fragments recovered from a sample. Sanger sequencing, 
on the other hand, allowed for exact base-by-base identification of a DNA fragment. 
These approaches were expensive and inefficient, despite their importance in early 
sequencing attempts [23]. Next Generation Sequencing Technologies (NGSTs)23 
have evolved as a result of years of research and development to solve these dif-
ficulties. NGSTs are a cost-effective addition to the BAC and Sanger sequencing 
technologies, allowing for high-dimensional and parallel sequencing [24].
Whole-genome sequencing and whole-exome sequencing are examples of 
genomics-related technology. There are a variety of commercial technologies for 
detecting gene mutations, SNPs, and copy number changes. The Cancer Genome 
Atlas (TCGA) is a joint project of the National Cancer Institute (NCI) and the 
National Human Genome Research Institute that began in 2005. In thirty-three 
Figure 2. 
The cancer immunogram. The schema depicts the seven parameters that characterise aspects of cancer-immune 
interactions for which biomarkers have been identified or are plausible. Italics represent those potential 
biomarkers for the different parameters (adapted from [20]).
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kinds of cancer, including head and neck SCC, the TCGA has created complete, 
multidimensional maps of important genetic alterations. Oral and oropharyngeal 
SCC has two different subgroups, according to thorough genetic profiling: HPV-
negative cancers that commonly develop in the oral cavity and lips; and HPV nega-
tive cancers of the oral cavity and lips in particular. The molecular changes in these 
two subgroups of SCC correspond to their clinical behaviour and patient prognosis. 
The TCGA database demonstrated that the vast majority of HPV negative OSCCs 
have TP53 loss-of-function mutations and CDKN2A inactivation, which is consis-
tent with previous findings. In addition, HPV negative OSCC showed a high amount 
of heterogeneity, according to integrated genomic analysis [25, 26]. Whole-exome 
sequencing, a transcriptomics approach for sequencing all of a genome’s expressed 
genes, revealed new mutations that had been missed in prior studies (known as the 
exome. NOTCH1 mutations were found in around 15% of the patients, while muta-
tions and focal copies of NOTCH1 were found in about 15% of the cases. NOTCH1 
mutations were found in about 15% of cases, and NOTCH2/3 mutations and 
localised copy-number changes were found in another 11% of OSCC cases [27, 28].
OSCC’s incredible diversity exemplifies how precision medicine may actu-
ally help patients and enhance medical care. The Pan Cancer Analysis of Whole 
Genomes project (PCAWG) is now steered to reveal noncoding driver mutations, 
such as alternative promoter usage, splicing, expression, editing, fusion, allele spe-
cific expression, and nonsynonymous variants, as it progresses from whole-exome 
sequencing to whole-genome sequencing [29]. MiRNAs and long noncoding RNAs 
(lncRNAs) are two types of noncoding transcripts. These noncoding transcripts, 
including miRNAs and long noncoding RNAs (lncRNAs), have a lot of potential for 
clinical research [30, 31].
2.3.1.2 Omics
While genomic data is crucial for establishing a full understanding of disease 
progression and therapeutic effects in physiological systems, intermediate omics 
levels such as the transcriptome, proteome, and metabolome are used to bridge the 
gap between genotypic effect and phenotypic event.
2.3.1.3 Transcriptomics
The transcriptome is the total mRNA within an individual or sample. Microarray 
and RNA sequencing (RNA-Seq) are two modern high-throughput sequencing 
approaches for collecting transcriptome data. Microarray analysis measures the 
amount of hybridization between a sample and corresponding probe to determine 
mRNA expression. The quantity of fluorescence seen within each well of the array 
corresponding to a given probe indicates the abundance of gene expression within 
a sample. Microarray analysis is constrained by the fact that designing probes 
requires prior knowledge of the gene’s sequence. This approach is similar to Sanger 
sequencing in that it determines the mRNA sequence by adding fluorescently 
tagged nucleotide bases one by one. During each loop, fluorescent pictures are 
recorded, and their analysis shows the exact sequence as well as its expression level. 
Microarray analysis takes less time to prepare samples than RNA-Seq, although 
RNA-Seq does not require prior knowledge of gene sequences and may handle fewer 
samples. Both technologies have tremendous throughput capacities, but microarray 
has a higher cost-value at the moment [32, 33].
Genomic profiling enables modern medication development, which often 
includes either microarray analysis or RNA-Seq for transcriptome profiling. Both 
microarray and RNA-Seq analyses allow for the identification of disease phenotype 
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and medication effect within a system (single cell or bigger), which is crucial for 
the development of genome-specific therapeutics. Although RNA-Seq looks to be 
more advantageous for discovering novel genomic medication effects and disease 
characteristics, microarray analyses are less expensive and have more standardised 
techniques. In general, RNA-Seq results are better for clinical research since they 
have a lower signal-to-noise ratio than microarray results. Furthermore, as com-
pared to microarray approaches, RNA-Seq results can be obtained from smaller 
sample quantities — nanogram versus microgram masses, respectively. As NGSTs 
become more widely used in clinical diagnostics, RNA-Seq methods are expected to 
become more standardised, eventually replacing microarray diagnostics [33, 34].
With transcriptomics technology, extensive attempts have been made to define 
OSCC at the molecular level. Reliable biomarkers are necessary to ease the predic-
tion of clinical outcome and evaluate therapy efficacy in order to optimise thera-
peutic regimens for the management of OSCC. Dysregulation of several pathways 
(e.g., mRNA processing, cytoskeletal organisation, metabolic processes, cell 
cycle regulation, and apoptosis) was discovered when assessing a cohort of OSCC 
transcriptomes [35]. OSCC has also been recommended for molecular characterisa-
tion, similar to lung SCC [36]. Dysregulation of the KEAP1/ NFE2L2 oxidative 
stress pathway is one of the signalling pathways that has been impacted, SOX2 and 
TP63 lineage markers, as well as PIK3CA and EGFR mutations, were used differ-
ently. Different activation patterns of the EGFR pathway are linked to clinically 
diverse behaviours [37]. A molecular signature has also been proposed to help with 
OSCC treatment planning by predicting the existence of lymph node metastases 
using the primary tumour at the time of diagnosis [38]. Furthermore, microarray 
results demonstrated BGH3, MMP9, and PDIA3 upregulation in more than 80% of 
OSCC tumours, implying the relevance of ECM-cell receptor interactions in OSCC 
progression [39]. These transcriptional markers may be useful in the development 
of customised therapy regimens for the treatment of OSCC in the future.
2.3.1.4 Proteomics
The term “proteomics” refers to the process of identifying and cataloguing all 
proteins in a biological system, as well as their relationships. Protein structure, 
quantities, and cellular localizations, protein–protein interactions, and protein 
production and breakdown rates are all revealed by proteomic analysis. This data 
is utilised to figure out how the proteome changes throughout various biological 
activities and to spot disease patterns. Data on post-transcriptional alterations, or 
the quantity of proteins in a tissue, may be useful for illness diagnosis, progression, 
and treatment in the case of PPM. Mass spectrometry (MS) has been the primary 
instrument for gathering proteomic data for the past two decades, particularly to 
assess protein expression, identify protein modification sites, and analyse protein–
protein interactions [40, 41].
The cellular abundance of proteins is primarily controlled by the quantity 
of translation, according to a landmark study published in 2011 that measured 
absolute mRNA and protein abundance and turnover using parallel metabolic 
pulse labelling [42]. Despite the fact that mRNA and protein levels are related to 
some extent, genome-wide protein abundance remains an important metric in 
determining cellular state and function. Intracellular and secreted proteins in body 
fluid specimens (e.g., serum, plasma, urine, and saliva) can be investigated using 
high-throughput total and phosphorylated protein analysis [43]. Alterations in 
protein expression in cell metabolism, adhesion, motility, and signal transduction 
have been discovered using proteomic analysis combined with in situ hybridization 
or immunohistochemistry [44, 45]. Promising results have been seen in studies. 
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Outcomes of salivary or serum proteomics in identifying OSCC and normal samples 
Analyses with a sensitivity and specificity of up to 90% [46, 47].
2.3.1.5 Metabolomics
The identification and analysis of metabolites, which are small-molecule inter-
mediate products in metabolic reactions, is referred to as metabolomics. Because 
metabolites reflect both hereditary and environmental factors, a comprehensive 
metabolic examination is typically referred to as a “functional readout” of the 
current status of the organic system. The Human Metabolome Database (HMDB) is 
a freely accessible web resource that contains complete information on the human 
metabolome. The human metabolome is made up of peptides, lipids, amino acids, 
nucleic acids, carbohydrates, organic acids, biogenic amines, vitamins, minerals, 
and other tiny molecules found in the human body. The overall number of metabo-
lites in HMDB 4.0 has increased dramatically from 40 153 in HMDB 3.0 to 114 100 
in HMDB 4.0. This equates to approximately a fivefold increase [48].
In the context of PPM, metabolomic data could provide insight into an individual’s 
unique physical reaction to a medicine, a technique known as metabolomics [49]. 
Currently, metabolomic studies of biofluids and tissues have aided in the develop-
ment of PPM methods by discovering illness biomarkers that have the potential to aid 
doctors in diagnosis and early treatment. Because metabolites, unlike most proteins, 
travel throughout the body and appear in easily accessible biofluids like blood and 
urine one of the primary clinical advantages of metabolomics is that measurements 
may be conducted noninvasively [50]. Nuclear magnetic resonance (NMR) spectros-
copy was commonly employed to identify metabolites in the early days of metabolo-
mics research, but over the last decade, there has been a big movement toward MS, 
which offers superior resolution and sensitivity to small concentrations [51, 52].
Metabolite profiling of tissue and body fluid specimens with the purpose of 
biomarker discovery in OSCC research has revealed significant changes in energy 
metabolism pathways, according to mass spectrometry-based metabolomics 
analysis (eg, glycolysis and tricarboxylic acid cycle) [53]. Glycolytic metabolites 
(e.g., glucose) had higher amounts in OSCC patients’ serum, while specific amino 
acids have lower levels (ie, valine, tyrosine, serine, and methionine) [54]. In OSCC 
tumour tissues, however, similar metabolite expression patterns are reversed, 
implying that this signature panel could be used as a screening tool. Early research, 
on the other hand, must be backed up with well-designed tests. Lipids have also 
been discovered as a significant class of metabolites, and abnormal cholesterol 
levels in the blood have been associated to a variety of cancers [55–57]. Total lipids, 
cholesterol, and high-density lipoprotein levels were shown to be considerably 
lower in OSCC patients compared to healthy controls [58, 59]. These lipidomic 
observations, albeit preliminary, may indicate greater usage of novel membrane 
synthesis by neoplastic cells and require further exploration.
These technologies will be collectively strong, with the potential to disclose 
molecular mechanisms and critical signalling pathways driving the disease, thanks 
to the rapid development of the omics tools outlined above. Furthermore, these 
tools have the potential to be utilised to identify new therapeutic targets as well as 
biomarkers that can be used to diagnose disease Cancer diagnosis, prognosis predic-
tion, and treatment surveillance could all benefit from this technology.
2.3.1.6 Companion diagnostics (CDx)
The US FDA produced the first regulatory guideline document on CDx in 2014, 
and it was here that this type of assay was officially defined for the first time [60]. 
Oral Cancer - Current Concepts and Future Perspectives
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A CDx test is an in vitro diagnostic equipment that delivers information necessary 
for the safe and effective use of a related therapeutic product, according to this 
definition. This means that testing with this sort of assay is required and must be 
disclosed in both the medication and CDx assay labelling. CDx devices help clini-
cians provide the most effective, tailored medicines for their patients. In specific 
sections of DNA, relevant genetic information for defining malignancies can be 
identified (i.e., oncogenes). Some CDx are based on these specific oncogenes and 
can be used to evaluate whether or not a person will respond to a certain treatment 
in order to avoid sequencing the entire genome and obtaining superfluous infor-
mation. Each CDx is linked to a certain medicinal treatment, which is linked to a 
particular genetic defect for which it is most effective [61]. Within the category of 
CDx products, there are a range of diagnostic procedures, each with its own role. 
Immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and real-
time quantitative PCR (RT-qPCR) are examples of these techniques [62].
2.3.1.7 Data storage
After collecting the OMICS data, storage and analysis also poses a great chal-
lenge. The International Cancer Genome Consortium (ICGC) and The Cancer 
Genome Atlas (TCGA; sponsored by the National Cancer Institute and the National 
Human Genome Research Institute) are two large databases for oncology data. 
The data gateway of the International Cancer Genome Centre (ICGC) focuses on 
50 tumour types and defines them on genomic, transcriptomic, and epigenomic 
levels across genders, mutations, tumour stage, and other factors. The TCGA portal 
has thorough information on genetic alterations and gene expression in 11 differ-
ent types of cancer tissues and 33 different cancer subtypes. On a large number 
of patients, analysis is performed on high-quality tumour samples and matched 
normal tissue samples [63, 64].
2.4 Single nucleotide polymorphisms (SNPs)
Despite the lifestyle habits of exposure to high risk factors for oral cancer with 
80% attributable risk of tobacco per se, a small proportion of the tobacco habit 
develop persistent premalignant lesions, and 3–8% transform to the malignant 
phenotype. Genomic variants, somatic mutations and epigenetic regulation play a 
critical role in oral cancer. SNPs are the most common genomic variants. SNPs are 
single base changes in a gene’s exonic coding region or non-coding intronic regions 
that affect gene expression and function directly or indirectly in more than 1% of 
an ethnic population. SNPs in intronic regions may modify the three-dimensional 
structure of DNA, causing changes in molecular attributes such as Gibbs free 
energy aectLnJ stability, as well as impacting DNA polymerase activity and tran-
scription factor activity. Binding SNPs can be found in one or both alleles, giving 
rise to heterozygous or homozygous genotypes. The wild-type (WT) allele is the 
ancestral allele, while the SNP allele is the changed allele. In a cancer case–control 
group, the frequency of allelotypes and genotypes differed, indicating a link 
between SNPs and cancer [65].
The connection of SNPs with risk propensity or susceptibility to oral cancer has 
been studied in several populations. In a meta-analysis research, the authors anal-
ysed SNPs in oral cancer and identified 34 SNPs in 30 genes that are strongly linked 
with oral cancer [66]. SNP rs1800471 in TGF- gene, with GC genotype associated 
with increased risk and GG genotype with lower risk in numerous studies and 
populations; SNP rs1048943 in CYP1A1 gene, with AG + GG genotypes resulting 
in increased risk and WT AA genotype resulting in decreased risk. The GSTM1 
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null genotype was linked to an elevated risk, while the WT genotype was linked to 
a lower risk. Similarly, heterozygous genotypes of SNPs rs1800870-AG in the IL-10 
gene, rs11549467-GA in the HIF gene, and rs861539-CT in the XRCC3 genes were 
linked to an increased risk of oral cancer, while WT genotypes were linked to a 
lower risk. The WT genotypes rs1801133-CC in MTHFR and rs20417-GG in COX-2, 
on the other hand, were related with an increased risk, while the corresponding 
SNP homozygous genotypes TT and CC were associated with a decreased risk [67].
SNP analysis using high-throughput genomic analysis, as reported in genome-
wide association studies (GWAS), and next-generation sequencing has emerged as 
a strong tool for identifying susceptibility loci, allowing information on thousands 
of SNPs to be obtained at the same time. These platforms often work with smaller 
samples and are more expensive, thus they must be confirmed in larger samples 
using alternative technology such as nucleotide sequencing and real-time PCR.SNPs 
investigated in various studies contribute to increased susceptibility to oral cancer, 
and a panel of SNPs could be used as Predictive Biomarkers to screen high-risk 
individuals who are prone to oral cancer due to tobacco use, providing an objective, 
unbiased test assay to assess oral cancer risk in individuals [66].
2.5 Developing a PPM therapy
2.5.1 The application of omics data to treatment
Establishing the link between biological data, disease, and clinical translation is 
a fundamental difficulty in PPM: how can we understand the data collected to make 
meaningful medical decisions? In the medical field, “Big Data” refers to a larger 
collection of medical data encompassing the tracking of various medical indicators 
and biomarkers across thousands of individuals (primarily clinical and omics data). 
Researchers may test tissues for thousands of molecular targets using high-through-
put data gathering, effectively recording the response of a complex system over time.
The reconciliation of various omics components allows for the generation of 
prediction models of human physiology that may be employed in experimental 
design and clinical trial development in the field of systems biology [68].
Systems biologists and bioinformatic scientists use statistically significant trend 
detection approaches to link observations to biological events and phenotypes. 
Multivariate decomposition techniques, predictive modelling and optimization 
strategies, and other statistics-based tools are examples of these. Statistically under-
standing Big Data trends is a separate field that is required for predictive modelling, 
clinical decision-making, and assistance [69].
Drug discovery techniques for a number of PPM cancer products have been 
developed thanks to advances in omics technologies. Circulating tumour cells 
(CTC) and DNA detection approaches have promise not just for early diagnosis, 
but also for personalised patient risk monitoring and the development of effective 
personalised therapy. Several other cancer medicines in development take advan-
tage of the immune system’s particular power and specialisation to fight cancer. This 
has been the focus of research for almost a century, and it has evolved into a distinct 
discipline known as immunoengineering. The ultimate goal of this profession is to 
tailor a more particular and potent immune response, which can lead to a powerful 
and effective personalised cancer treatment [70].
2.5.2 Early cancer detection using CTCs and DNA
CTCs and circulating tumour DNA (ctDNA), two forms of oncological 
biomarkers, have emerged as the face of non-invasive cancer diagnosis using 
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“liquid biopsy” procedures. Because research has shown that tumours release 
both types of biomarkers into the circulation early in cancer progression, there 
has been a lot of focus on their use in early detection and screening. CTCs and 
ctDNA are likely to become more effective in risk stratification, illness moni-
toring, and tailored treatment selection as research progresses and technology 
improves [71].
230 OSCC patients at various pathological stages of the disease and treatment 
modes were enrolled in a cross-sectional observational study. CTCs were obtained 
utilising the Onco Discover liquid biopsy method, which is based on immunomag-
netic CTC enumeration and has been authorised by the Drug Controller General of 
India. The presence of CK18 and well-defined, DAPI-stained nuclei were found in 
CTCs. CTC were counted and then examined for stage, extracapsular spread (ECS), 
lymphovascular emboli (LVE), perineural invasion (PNI), and depth of invasion, 
among other clinicopathological criteria (DOI). To distinguish between early and 
advanced stages of dialysis, CTC cut off values were obtained. CTCs in OSCC 
patients were found to be associated with cancer stages (clinical and pathological) 
and aggressive pathological characteristics. We saw a 25–50 percent increase in CTC 
number when aggressive clinical characteristics were present, which frequently 
indicate a bad prognosis. Treatment-naive patients had a reduced number of CTCs 
in the early stages. The number of CTCs in advanced-stage OSCC patients was 50% 
greater than in early-stage OSCC patients. CTC might be considered a trustworthy 
measure to predict the disease outcome in oral cancer due to a positive connection 
of CTC number with numerous pathophysiological characteristics. The presence 
of CTC at all stages of the disease shows that OSCC is most likely a biologically 
systematic disease [72].
2.5.2.1 Organoids
Patient-derived tumour organoids, which serve as in vitro tumour models and 
predictors of medication responses, are one strategy now under investigation for 
customised cancer treatment. In vitro cancer cell lines, patient-derived xenografts, 
and 3D culture models are all used in traditional cancer research and therapy. 
Due to the diversity and variability of the tumour microenvironment, these are 
restricted in their ability to precisely correlate an individual tumour’s response to a 
treatment. Organoids provide a more faithful depiction of this dynamic niche, and 
data suggests that the genetic and functional similarities between patient-derived 
tumour organoids and the real thing are striking [73].
2.5.3 Targetted mononclonal antibodies for cancer therapy
Because of their low cytotoxicity, high specificity, and scalability, mAbs have 
proven particularly promising for cancer therapies among the numerous molecular-
based approaches (e.g., small compounds, mAbs, and vaccines). mAbs are Y-shaped 
proteins that can attach to a specific molecular target and are created either 
synthetically or by B lymphocytes. mAbs are one of the most rapidly expanding 
immunotherapies, with over 22 FDA-approved mAb-based oncology medicines. 
mAb-based therapies, in contrast to standard therapies (e.g., surgery, radiation, 
and/or chemotherapy), are targeted to specific molecular markers expressed by a 
specific tumour, and so are more likely to be effective [74]. Typically, monoclonal 
antibodies (e.g., cetuximab) or synthetic small molecules are used to target cancer-
specific cell receptors or intracellular signalling pathways (eg, gefinitib) in OC [9]. 
The tested drugs include, Cetuximab (Erbitux), pembrolizumab (Keytruda) and 
nivolumab (Opdivo).
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Anti-EGFR monoclonal antibodies (mAbs) possess an antibody-dependent 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and 
antitumor activity. Mice study has shown EMab-17(Anti-EGFR mAb) may be used 
as an antibody-based therapy for EGFR-expressing OSCC [75].
2.5.3.1 Immune check point inhibitors
The creation of antibodies capable of blocking coinhibitory immune cell recep-
tors, or “immune checkpoints” — T-cell surface receptors that, when activated by 
specific ligands, limit the T-cytotoxic cell’s immunological response — is a hopeful 
improvement in cancer treatment. Tumour cells tend to overexpress the ligands 
that activate these inhibitory receptors, allowing them to evade the immunological 
response of T cells and proliferate freely. Despite the fact that over two dozen indi-
vidual costimulatory receptors have been identified, two of them — CTLA-4 and 
programmed cell death 1 (PD-1), have been the focus of antibody-based immune 
checkpoint blockade (ICB) treatments [76].
2.5.4 Non-invasive imaging for immunotherapy
Most of the patients do not respond to immunotherapy especially the immune 
check point inhibitors (ICI). The traditional imaging methods only provide ana-
tomic information and do not define the concrete representation of response or 
progression, especially pseudo-progression due to tumour infiltrating lymphocytes 
(TILs); and third, toxicities are a potential concern for the widespread use of 
immunotherapy, which is associated with an increased risk of cancer progression. 
As a result, a reliable and repeatable imaging approach is critical for identifying the 
patient group most or least likely to react to immunotherapy [77].
Molecular imaging, in combination with disease-specific imaging probes, can 
provide non-invasive, early, and dynamic information about the effects of immune 
cells or other cells in the tumour microenvironment (TME), as well as target 
Figure 3. 
Translation of PPM in to clinical practice.
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expression and biodistribution of immunomodulatory drugs in the body, allow-
ing clinicians to predict which patients will benefit most from immunotherapy. 
Furthermore, integrating immunotherapy with molecular imaging may improve 
cancer immunotherapy precision. Immunotherapies are classified into four major 
categories: Immune cell-based therapies, ICIs, tumour vaccines, and CAR-T cell 
therapy are all examples of this [78].
Figure 3 summarises the translation of PPM in to clinical practice.
3. Conclusion
This chapter has discussed the various aspects of PPM and the use of molecular 
and genetic profiling of tumours through omics technology for early diagnosis, 
formation of patient specific databases through next generation sequencing and tai-
lored immunotherapy. Despite the advances in development technologies very few 
studies have been conducted in relation to OC and the research in this arena is in its 
budding stage. Future clinical trials on OC treatment should focus on translating 
the OMICs technology from bench to bedside with the use of biomarkers and CDx 
technologies. Tailored treatment therapies should be planned according to patients 
molecular and genetic profiling with consideration of individual factors. Pharma 
developers should create an effective medicine combining the traditional clinical 
data with a patient’s biological profile, which includes a variety of omics-based 
statistics. The databases can be used to gather knowledge about disease and aid in 
its development more precise, safer, and better-targeted medicines for a variety of 
diseases in patient population.
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